Reports from Vanderbilt University highlight recent research in respiratory syncytial virus vaccines
2007 NOV 19 -- Fresh data on respiratory syncytial virus are presented in the report 'The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines.' According to a study from the United States, "Early in the development of respiratory syncytial virus (RSV) vaccines severe disease occurred in children after receipt of formalin-inactivated RSV vaccine. Continuing efforts to develop an appropriately attenuated and immunogenic live RSV vaccine have given opportunities to assure that live vaccines are safe through surveillance of children after vaccination." "In the present study, the rate of RSV-associated upper respiratory tract illness in 388 children was lower in RSV vaccinated children than in controls (14% versus 20% in a 6-24 month old group and 16% versus 25% in infants). Additionally, there was no evidence that vaccination predisposed to more severe lower respiratory tract illness. Thus infection with a series of live attenuated RSV vaccines did not result in enhanced disease upon infection with wild type RSV," wrote P.F. Wright and colleagues, Vanderbilt University. The researchers concluded: "The impact of RSV during this surveillance will inform the design of future efficacy studies with RSV vaccines." Wright and colleagues published the results of their research in Vaccine (The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine, 2007;25(42):7372-8). For additional information, contact P.F. Wright, Vanderbilt University, Nashville, TN USA.. The publisher of the journal Vaccine can be contacted at: Elsevier Science Ltd., the Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. Keywords: United States, Nashville, Respiratory Syncytial Virus Vaccines, Biotechnology, Infectious Disease, Pulmonology, Respiratory Syncytial Virus, Vaccines. This article was prepared by Pharma Business Week editors from staff and other reports. Copyright 2007, Pharma Business Week via NewsRx.com.
|
